Evidence map›Paper›PMID 41552600›Full record

ArticleACS omega2026

Integrating Proteomics and Predictive Model: Elucidating the Role of Aminated Nanodiamonds in Suppressing Prostate Cancer Growth.

Wenjie Xie, Qianfeng Xu, Zeheng Tan, Jundong Lin, Fen Zou, Muqi Chen, Jiaquan Xu, Guowei Zhong, Qiuling Du, Jinxiang Zhang and 8 more

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Wenjie XieDepartment of Urology, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Qianfeng XuDepartment of Urology, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Zeheng TanDepartment of Urology, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Jundong LinGuangdong Provincial Key Laboratory of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510230, China.ORCID https://orcid.org/0000-0001-7068-2172
Fen ZouDepartment of Urology, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Muqi ChenDepartment of Urology, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Jiaquan XuDepartment of Urology, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Guowei ZhongDepartment of Urology, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Qiuling DuDepartment of Urology, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Jinxiang ZhangDepartment of Urology, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Jibiao LiDepartment of Urology, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Minyao JiangGuangzhou Laboratory (No. 9 XingDaoHuanBei Road, Guangzhou International Bio Island), Guangzhou, Guangdong Province 510005, China.
Ming XiGuangzhou Laboratory (No. 9 XingDaoHuanBei Road, Guangzhou International Bio Island), Guangzhou, Guangdong Province 510005, China.
Wei HuaGuangzhou Laboratory (No. 9 XingDaoHuanBei Road, Guangzhou International Bio Island), Guangzhou, Guangdong Province 510005, China.
Yangjia ZhuoDepartment of Urology, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.ORCID https://orcid.org/0000-0003-3061-7303
Yixun ZhangDepartment of Burn and Plastic Surgery, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Qishan DaiDepartment of Urology, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
Weide ZhongDepartment of Urology, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.ORCID https://orcid.org/0000-0002-0430-2845

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) presents a formidable therapeutic challenge owing to the limited efficacy of existing treatments. In this study, a series of comparative experiments demonstrated that nanodiamonds (NDs) with different functional groups exhibit inhibitory effects on the growth, replication, and migration of prostate cancer cells without directly killing the cells. Among them, aminated nanodiamonds (aNDs) showed the most pronounced inhibitory activity. Subsequently, a combination of proteomics analysis and machine learning was employed to elucidate the molecular mechanisms by which these aNDs exerted their inhibitory effects on PCa progression. Data-independent acquisition proteomics identified the key proteins affected by the aNDs, and the Kyoto Encyclopedia of Genes and Genomes analysis revealed ribosome pathway enrichment. Bioinformatics analysis focused on ten crucial genes, thus incorporating a novel prognostic model that categorized patients based on gene expression and emphasized the significance of mitochondrial ribosomal protein L22 (MRPL22). In vivo experiments confirmed the antitumor effects and biocompatibility of the aNDs. In addition, an analysis of the response of MRPL22 to anticancer drugs in public databases revealed its relevance to a range of drugs and compounds. In summary, this study integrated diverse interdisciplinary methodologies, thereby offering insights into the mechanism of the inhibition of PCa by the aNDs and the regulatory role of MRPL22 in the ribosomal pathway.

Identifiers

PMID41552600
PMCPMC12809566

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.